Overview

A Study to Compare Efficacy, Pharmacokinetics, Safety and Immunogenicity of MB04 [proposed Etanercept Biosimilar] to Enbrel® [EU-sourced] in Rheumatoid Arthritis

Status:
RECRUITING

Trial end date:
2026-01-01

Target enrollment:

Participant gender:

Summary

A study to compare efficacy, pharmacokinetics, safety and immunogenicity of MB04 \[proposed etanercept biosimilar\] to Enbrel® \[EU-sourced\] in rheumatoid arthritis

Phase:

PHASE3

Details

Lead Sponsor:

mAbxience Research S.L.

Treatments:

Etanercept